Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of this study is to determine if trabecular or cortical volumetric bone mineral density (vBMD) change over time in postmenopausal breast cancer patients who are prescribed Anastrozole, as measured by pQCT at the proximal and distal radius and tibia.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamilton Health Sciences Corporation
• Collaborator: Canadian Institutes of Health Research (CIHR)
• Treatments: Anastrozole

Criteria

Inclusion Criteria:

Group 1: Treatment Group

• Postmenopausal breast cancer patients (stage 1 and 2)

• Non-institutionalized

• Prescribed Anastrozole within the preceding 1-2 weeks

• Ambulatory

• Ability to read and comprehend study protocol and informed consent

Group 2: Control Group

• Healthy, age-matched postmenopausal women

• Non-institutionalized

• Ambulatory

• Ability to read and comprehend study protocol and informed consent

Exclusion Criteria:

• Prior Tamoxifen or Raloxifene therapy

• Known congenital metabolic bone disease (e.g., osteogenesis imperfecta)

• Concomitant treatment with corticosteroids

• Patients with a history of endocrine disorders or surgical parathyroidectomy

• Patients with disorders known to affect bone metabolism including diabetes mellitus, systemic lupus erythematosus, Cushing's disease, hyperparathyroidism, chronic liver disease, chronic renal failure, Paget's disease

• Conditions preventing pQCT measurement (e.g., unable to lie flat or still for 15 minutes)

• Geographically inaccessible for follow-up